Navigation Links
Gemin X Pharmaceuticals Selects and Deploys Clinical Force CTMS
Date:4/6/2009

Clinical Force, a web based CTMS (Clinical Trial Management System), has announced that Gemin X Pharmaceuticals has selected and deployed Clinical Force to manage worldwide clinical trials. "We have deployed the Project Management, Regulatory/Ethics Management, CRF Tracking, Visit Reports, and Site Payments modules as well as the Offline Client. Future phases of our project will include integration to our EDC system(s), rollout of the new Clinical Supplies module" said Kevin Rechkemmer, Clinical Information Science Manager, Clinical Operations, Gemin X Pharmaceuticals.

Raleigh, NC (PRWEB) April 6, 2009 -- Clinical Force, the first SaaS, software as a service, CTMS, announces that Gemin X Pharmaceuticals has selected Clinical Force to manage worldwide clinical trials.

As an emerging biotech company working in oncology therapeutics with operations in Montreal Canada and Malvern Pennsylvania, Gemin X Pharmaceuticals selected Clinical Force based on its cost effective monthly subscription fees, adaptable infrastructure requiring no internal IT investment or support, and flexible user interface. In addition, Gemin X expects to improve study efficiencies by requiring their CROs to use Clinical Force on outsourced studies.

"After an extensive review process we felt Clinical Force's modular and cost effective solution met our needs. We have deployed the Project Management, Regulatory/Ethics Management, CRF Tracking, Visit Reports, and Site Payments modules as well as the Offline Client. Future phases of our project will include integration to our EDC system(s), rollout of the new Clinical Supplies module as well as other innovative functional changes to the system that will lead to process efficiencies and cost savings," said Kevin Rechkemmer, Clinical Information Science Manager, Clinical Operations, Gemin X Pharmaceuticals.

About Clinical Force
Clinical Force delivers a fully functional Clinical Trials Management System (CTMS) to Clinical Research Organizations and Sponsors. Clinical Force is the first company to deliver the CTMS in the Software as a Service (SaaS) model enabling quick installation and a cost effective solution. Organizations in North America, South America, Africa and Europe are successfully using the CTMS to improve internal efficiencies and real time visibility of all studies from an easy to use web based solution. Clinical Force is a privately held company with strong life science pedigree, the company has offices in the US and Europe. www.clinicalforce.com

About Gemin X Pharmaceuticals
Gemin X is developing first-in-class cancer therapeutics based on reinitiating programmed cell death, or apoptosis, inducing cancer cell self-digestion, or autophagy, and the inhibition of metabolism in cancerous cells. Gemin X currently has several clinical development programs underway, including Phase 2 clinical trials for its lead product candidates obatoclax (GX15-070), an innovative pan Bcl-2 inhibitor, and GMX1777, a novel inhibitor of NAD+ synthesis, and preclinical studies for its Telomere Capping and SMAC Mimetic programs. Potential treatment indications for the full scope of pipeline programs span a broad range of hematological and solid tumors, including mantle cell lymphoma (MCL), melanoma, glioblastoma, small cell lung cancer (SCLC), refractory acute lymphoblastic leukemia (ALL) and mastocytosis.

For more information, please visit www.geminx.com

###

Read the full story at http://www.prweb.com/releases/CTMS/biotechnology/prweb2292394.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
2. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
3. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
4. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
5. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
6. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
7. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
8. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
9. VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... ... October 10, 2017 , ... For ... has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled ... Volunteer Experience from US2020. , US2020’s mission is to change the trajectory of ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology:
(Date:10/4/2017)...  GCE Solutions, a global clinical research organization (CRO), announces the ... on October 4, 2017. Shadow is designed to assist medical writers ... 0070 of the European Medicines Agency (EMA) in meeting the requirements ... ... ...
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017  IBM ... in dairy research, today announced a new collaboration using ... the chances that the global milk supply is impacted ... project, Cornell University has become the newest academic institution ... Chain, a food safety initiative that includes IBM Research, ...
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
Breaking Biology News(10 mins):